Gordon Wishart
| Professor Gordon C Wishart | |
|---|---|
| Born |
3 September 1960 Edinburgh |
| Nationality | United Kingdom |
| Fields | Medicine |
| Institutions | Addenbrooke’s Hospital, Cambridge BreastHealth UK |
| Alma mater | Edinburgh University |
| Known for | Treatment of breast cancer |
Professor Gordon C Wishart MB ChB MA(Cantab.) MD FRCS FRCS (Eng.) FRCS (Gen.) is a consultant breast & endocrine surgeon at Addenbrooke's Hospital, Cambridge. He is distinguished for his pioneering work in the treatment of breast cancer, where he has introduced innovative, and sometimes controversial, techniques which have subsequently seen wide acceptance and adoption.
Early life and education
Gordon Cranston Wishart was born in Edinburgh, Scotland, on 3 September 1960.
He studied at Edinburgh University Medical School, where he obtained his MB ChB (Bachelor of Medicine, Bachelor of Surgery) degree in July 1983.
He subsequently obtained his MD from Edinburgh University in June 1992 with a thesis entitled Aspects of multidrug resistance in breast cancer.[1]
Research and publications
Gordon Wishart is notable for his prolific clinical research output, alongside his work as a practising breast and endocrine surgeon. He has published widely and has received numerous prizes for his papers, including Best paper: British Association of Day Surgery 2002;[2] British Journal of Surgery Prize for best paper at British Association of Endocrine Surgeons, September 2006;[3] and British Journal of Surgery Prize for best paper at British Association of Endocrine Surgeons, September 2007.[4]
As of October 2009 he is principal investigator on the following studies:
- Reasons for improved survival in screen-detected breast cancer
- Development of a UK version of Adjuvantonline.
- Infrared Imaging for breast cancer diagnosis
- BT blood test for breast cancer detection
In addition he is co-investigator, surgical coordinator or clinical surgical coordinator on an additional 15 research studies.[5]
His research has been published in The Lancet,[6] the British Journal of Cancer,[7][8][9][10][11] the British Medical Journal,[12] the Journal of Clinical Oncology[13] and the British Journal of Surgery,[14][15] among others.
Major achievements
- In 1990, Gordon Wishart identified that P-glycoprotein, a trans-membrane export pump involved in multidrug resistance, was present in breast cancer.[16]
- In 1998, he introduced early patient discharge, with wound drains still in situ, following breast cancer surgery. Although controversial at the time this technique has since been widely adopted.[17]
- Wishart pioneered minimally invasive parathyroid surgery as a daycase procedure in the UK, together with the use of intra-operative parathyroid hormone (PTH) measurement for parathyroid surgery.[18]
- In 2007, Wishart piloted gold seed insertion following breast conserving surgery for breast cancer to facilitate targeted radiotherapy.[19]
- In 2009, he pioneered pre-operative axillary lymph node staging in breast cancer treatment.[20][21]
Current posts
Gordon Wishart currently holds the following posts:
- Medical Director, BreastHealth UK [22]
- Visiting Professor of Cancer Surgery, Anglia Ruskin University[23]
- Associate Lecturer, Faculty of Clinical Medicine, University of Cambridge[24]
He also acts as a referee for the British Journal of Surgery, the European Journal of Surgical Oncology, and Nuclear Medicine Communications
References
- ↑ Edinburgh University library catalogue entry for Aspects of multidrug resistance in breast cancer
- ↑ http://www.selectmysurgeon.com/profile/Breast/Gordon_Wishart/
- ↑ http://www3.interscience.wiley.com/journal/116324583/abstract
- ↑ http://www.baes.info/Pages/newsletter_November_2007.pdf British Association of Endocrine and Thyroid Surgeons, Newsletter, November 2007
- ↑ Gordon Wishart’s CV on Select My Surgeon
- ↑ The importance, availability and measurement of oestrogen receptor (ER) status in the management of breast cancer in the United Kingdom – results of a nationwide survey. BJ Mander, K Heal, AD Purushotham, GC Wishart. The Lancet 1998; 352: 36-37
- ↑ GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
- ↑ T Barrett, D J Bowden, D C Greenberg, C H Brown, G C Wishart, P D Britton. Radiological staging in breast cancer: which asymptomatic patients to image and how. British Journal of Cancer, 29 September 2009
- ↑ S J Dawson, S W Duffy, F M Blows, K E Driver, E Provenzano, J LeQuesne, D C Greenberg, P Pharoah, C Caldas, G C Wishart. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338-1344
- ↑ L Hughes-Davies, C Caldas, G C Wishart. Tamoxifen: the drug that came in from the cold. British Journal of Cancer 2009; 101: 875-878
- ↑ G C Wishart, D C Greenberg, P D Britton, P Chou, C H Brown, A D Purushotham, S W Duffy. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? British Journal of Cancer 2008; 98: 1741-1744
- ↑ BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
- ↑ GC Wishart, D Bissett, J Paul, D Jodrell, A Harnett, T Habeshaw, DJ Kerr, MA Macham, M Soukop, RC Leonard. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial J Clin Oncol, Sep 1 1994: 1771-1777
- ↑ Gurnell E.M., Thomas S.K., McFarlane I., Munday I., Balan K.K., Berman L., Chatterjee V.K.K., Wishart G.C. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
- ↑ Gupta, Y, Ahmed, R, Happerfield, L, Pinder, SE, Balan, KK, Wishart, GC. P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. British Journal of Surgery, 2007. 94(12) pp. 1491-1495
- ↑ GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
- ↑ BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
- ↑ Gurnell EM, Thomas SK, McFarlane I, Munday I, Balan KK, Berman L, Chatterjee VKK, Wishart GC. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
- ↑ Gold Seed Study: Evaluation of Tumour Bed Localisation and Image-guided Radiotherapy for Breast Cancer. On Behalf Of The Import Working Party, Coles CE, Wishart G, Donovan E, Harris E, Poynter A, Twyman N, Routsis D, Wilkinson J, Yarnold J. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):S26-7.
- ↑ Britton PD, Goud A, Godward S, Barter S, Freeman A, Gaskarth M, Rajan P, Sinnatamby R, Slattery J, Provenzano E, O’Donovan M, Pinder S , Benson J, Forouhi P, Wishart GC. Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. European Radiology 2009; 19: 561-569
- ↑ Britton P D, Provenzano E, Barter S, Gaskarth M, Goud A, Moyle P, Sinnatamby R, Wallis M, Benson J R, Forouhi P, Wishart GC. Ultrasound-guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? The Breast 2009; 18(1): 13-16.
- ↑ Breast Cancer Risk for Daughters
- ↑ Anglia Ruskin University – Pink Rose Appeal
- ↑ University of Cambridge – Graces to be submitted to the Regent House at a Congregation on 22 July 2006